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Purpose. Spanish retina specialists were surveyed in order to propose actions to decrease deficiencies in real-life neovascular age
macular degeneration treatment (nv-AMD).Methods. One hundred experts, members of the Spanish Vitreoretinal Society (SERV),
were invited to complete an online survey of 52 statements about nv-AMDmanagement with amodified Delphi methodology. Four
rounds were performed using a 5-point Linkert scale. Recommendations were developed after analyzing the differences between
the results and the SERV guidelines recommendations. Results. Eighty-seven specialists completed all the Delphi rounds. Once
major potential deficiencies in real-life nv-AMD treatment were identified, 15 recommendations were developed with a high level
of agreement. Consensus statements to reduce the burden of the disease included the use of treat and extend regimen and to
reduce the amount of diagnostic tests during the loading phase and training technical staff to perform these tests and reduce the
time between relapse detection and reinjection, as well as establishing patient referral protocols to outside general ophthalmology
clinics. Conclusion.The level of agreement with the final recommendations for nv-AMD treatment among Spanish retinal specialist
was high indicating that some actions could be applied in order to reduce the deficiencies in real-life nv-AMD treatment.
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1. Introduction
Age-related macular degeneration (AMD) is the most com-
mon cause of blindness in the Western world, and given its
chronic and progressive course altogether with the fact that
AMD may require lifelong observation and therapy, it has
become amajor socioeconomic issue as the proportion of the
aged population is increasing exponentially [1].The beneficial
effects of intravitreal injections of ranibizumab (Lucentis,
Genentech, Inc., South San Francisco, CA, and Novartis,
Basel, Switzerland) and aflibercept in the treatment of neovas-
cular AMD (nv-AMD) have been widely evidenced showing
significant improvements in visual acuity and quality of life
[2, 3]. The standard of care for nv-AMD was established on
basis of the results obtained in the pivotal randomized clinical
trials with fixed monthly injections of ranibizumab [2], albeit
a significant burden for patients, physicians, and health ser-
vices. Retinal specialists developed further modifications to
this monthly regime. For instance, an individualized dosing
strategy through a monthly follow-up with the decision to
treat based on optical coherence tomography (OCT) findings
and visual acuity changes arose as a potential alternative. Sev-
eral reports have shown that intravitreal antiVEGF therapy
with ranibizumab or with bevacizumab is effective inmainta-
ining or improving visual acuity on this “as-needed” basis, so
called pro re nata (PRN) strategy; [4–6] furthermore, ranibi-
zumab administered on an as-needed basis was a more cost-
effective strategy compared to fixed monthly treatments with
respect to cost per QALY gained [7].
More recently it has been reported that, after extended
follow-up periods, most patients exhibit persistent exudation
of the choroidal neovascularization (CNV) with moderate
vision loss with this PRN therapeutic approach [8]. The
HORIZON study demonstrated that after 3 and 4 years of
follow-up of patients with neovascular AMD, an incremental
decline of the VA gains seen during the first 2 years of the
studies took place after patients were switched to a PRN reg-
imen, suggesting that switching from a strict treatment regi-
men to a less frequent investigator-determined PRN dosing
was paralleled by signs of disease destabilization [9].
A variety of publications of cohorts of patients with nv-
AMD managed with a PRN strategy have been reported: a
Swedish study showed an increase of 1 letter after 12 months,
a Spanish showed an increase of 1.3 letters after 12 months,
and a German study reported a stabilization of vision after 24
months [10–12].
This significant worsening of visual acuity after 12–24
months of follow-up may be related to a decrease in the
number of follow-up visits and intravitreal drug injections
when comparedwith the clinical trials. For instance, a Danish
study with a mean number of injections of 8.7 in four years
found a significant decrease in vision through that period [8].
Individualized treatment regimens impose a considerable
burden for the patient, and good results might only be achi-
eved if patients were able and willing to accept these monthly
visits. However, the retinal physicians’ nonadherence to
the nv-AMD treatment guidelines and the health systems
organization may preclude an optimum treatment in some
patients, making the translation of the clinical trial results to
real life outcomes impossible.Thedecline in quality of life and
increased need of daily living assistance after long follow-up
of patients with nv-AMD substantiates the need for detecting
deficiencies in real-life treatment in order to prevent vision
loss and progression to blindness.
The purpose of this study was to perform a Delphi study
with Spanish experts in nv-AMD treatment to identify major
potential problems in its management and to propose actions
that may improve the final outcomes of these patients.
2. Methods
2.1. Study Design. A national survey was performed using a
modified Delphi process [13]. The Delphi process is an anony-
mous group facilitation technique that seeks to obtain con-
sensus on the opinions of experts through a series of struc-
tured questionnaires, called rounds. After each one of these
rounds the results are summarized and presented to the parti-
cipants for possible reconsideration of their opinion. The
anonymous nature of the Delphi technique ensures that a
single individual cannot dominate the consensus formation
and all participants are equally able to change their opinion
in the course of the process [14–16].
In the present study a modified Delphi method was used,
with the items to be surveyed previously selected by a general
coordinator and discussed with an expert panel instead of
provided by the participants.
2.2. Selection of Survey Targets. Retinal experts were identi-
fied representing proportionally all the regions in Spain acc-
ording to the following selection criteria: (1) Spanish Vitreo-
retinal Society (SERV) members; (2) active nv-AMD referral
specialist; (3) involvement in postgraduate training.
As there is no formal consensus about the number of
experts to be required for a Delphi study, a total of 100 retinal
physicians were distributed according to the number of peo-
ple aged over 50 years who live in the 52 Spanish provinces;
sixteen leading SERV members (expert panel) identified
these 100 experts based on the criteria afore mentioned.
The key issues about nv-AMD treatment to be surveyed
were identified by the study coordinator (Alfredo Garćıa-
Layana) and discussed with the expert panel based on the nv-
AMD SERV guidelines [17].
2.3. First Delphi Round. An anonymized questionnaire was
e-mailed to the 100 retinal physicians selected, including the
guidelines to rate how often they performed several tasks or
agree/disagree with different statements.Theywere requested
to submit an email to the study coordinator with any relevant
comment about the questionnaire and were encouraged to
suggest new items that should be considered for further ass-
essments. Each item was rated into a four-step scale provided
with response anchors (1 = almost never; 2 = sometimes; 3 =
frequently; 4 = almost always).
2.4. Second Delphi Round. The ratings resulting from the first
Delphi round were analyzed and the scores distribution was
presented to the expert panel revised in a presentational
Journal of Ophthalmology 3
meeting. All the submitted comments were addressed and
ambiguous questions were reformulated. The questions rem-
ained unchanged but clarification was allowed. All new
proposed elements were discussed and added next to the
questions describing similar items, if they were considered
relevant by the advisory panel. The study coordinator sub-
mitted the new survey to the entire participant pool that res-
ponded to the first round. Each one of the previous questions
was provided with an anonymous summary of the expert’s
opinion from the previous round.The study participants were
encouraged to revise their earlier answers in light of the
replies of other members of their panel. No elements were
excluded between the first and second rounds.
2.5.TheThird and Fourth Delphi Rounds. Thefinal content of
the assessment instrument was based on the consensus achie-
ved after the second Delphi round. Differences between the
results of the survey and the recommendations of the nv-
AMD SERV guidelines [17] were analyzed.Thereafter, a third
round with recommendations developed by the study coor-
dinator was resubmitted with the same strategy used for
the first round. Their opinions were measured using a five-
point Linkert scale ranging from strongly-agree to strongly
disagree. A fourth Delphi round was performed to review
their earlier answers in light of the replies of other members.
A predefined consensus level is an indicator good quality
and best practice guidelines suggest that criteria for consen-
sus should be defined in advance [18]. So, consensus was
predefined as more than 70% of the experts supporting an
element answering the item with “strongly agree” or “agree”
[19–21].
3. Results
One hundred retina specialists were selected from a total of
537 SERV members. Eighty-seven completed the first Delphi
round of answers, and 85 completed the second round. Sixty-
nine of them (81%) had more than 10 years of experience
treating vitreoretinal diseases. Forty-eight (56%) work both
in National Health Service (NHS) and private facilities, 29
(35%) only in NHS, and 8 only in private facilities. Table 1
summarizes the final answers for the second Delphi round
questionnaires. After the most important deficiencies were
detected, an expert advisory panel used a new two-round
Delphi method to describe some recommendations in order
to reduce some of the problems detected. Table 2 summarizes
the final recommendations from the expert panel.The fifteen
recommendations achieved an important consensus as all of
them were ranged as “strongly agree” or “agree” by more than
80% of the members of the advisory panel.
4. Discussion
Although patients usually show a good adherence to indi-
vidualized treatment strategies, the feasibility related to
ophthalmologist and Healthcare resources, in addition to an
increased number of patients with the need to be attended,
carries a major clinical issue with the consequence of vision
loss and suboptimal results compared to that achieved by the
pivotal clinical trials [22]. Using modified Delphi methodol-
ogy, a national panel of experts in nv-AMD treatment looked
for potential deficiencies in real-life nv-AMD treatment and
proposed 15 actions thatmay help to improve the outcomes of
patients with nv-AMD. The level of agreement with the final
recommendations among Spanish retinal specialist was high
indicating that some actions can be applied in order to reduce
disarrangements inpatient flow and nv-AMDmanagement.
The results of this analysis showed that there was a high
degree of agreement about the signs and symptoms to refer
a patient to a retina specialist (Table 1). However, the total
time spent in each visit might determine the total amount of
patients that can be efficiently attended during every working
day [23]. The extensive use of retina clinics in NHS facilities
might explain that a routine fluorescein angiography is not
always performed in all new cases and that an indocyanine
green angiography is infrequently done in an attempt to
reduce the time of the visit (Table 1). On the other hand,
the three initial consecutive monthly intravitreal injections
(loading phase) are almost always administered, as these
may not be perceived as a significant burden assuming that
they reduce the proportion of patients with vision loss [24].
However, during the loading phase scheduled visits, most
retina specialists performed visual acuity (VA) exams and
OCT imaging that might be avoided (Table 1). In addition,
few Spanish ophthalmologists consider that VA and OCT
should be always performed by technical staff, but instead by
themselves (Table 1).These two pointsmight lead to unneces-
sary diagnostic testing and lengthening of each visit. So to
define in each center an efficient structure where technicians,
optometrists and nurses have clear roles that allow a faster
patient flow might be mandatory.
Current Spanish and European guidelines recommend a
PRN dosing strategy after the loading dose, where injections
are administered when visual acuity loss and signs of lesion
activity occur [4–6, 17, 23]. This is probably the reason why
the most valued protocol for the follow-up of nv-AMD in
Spain turned out to be PRN (Table 1). However, this protocol
requires monthly monitoring visits which are considered the
biggest burden to deal with [23]. Time delays are frequent
beyond the recommended interval, and this might usually
result in preventable vision loss.
In order to lengthen the period between follow-up exam-
inations, a protocol called Inject and Extend or Treat and
Extend Regimen (TER) has also been described [25–27]. This
approach involves continuous maintenance treatment, but at
less than monthly intervals, with the dosing schedule deter-
mined by VA, clinical examination, and OCT findings [25–
27]. However, TER is not often used in Spain (Table 1).
The “wait and extend” strategy is considered by the Span-
ish retina physicians the least appropriate regimen, although
it is considered the most easily suitable in case of busy agen-
das, and consequently is frequently used in Spain (Table 1).
With this protocol, follow-up visits are progressively spread
out to a maximum of 8 weeks apart in the absence of visual
acuity loss and signs of lesion activity, but without reinjec-
tions unless the OCT images evidence exudative changes.
This regimen has shown to be efficient and safe in patients
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Table 1: Final answers for the second Delphi round questionnaires.
Question Almost never Sometimes Frequently Almostalways
Diagnosis and initial treatment
(1) Do you consider the metamorphopsia a red flag symptom? 0% 2% 15% 83%
(2) Do you consider a strong decrease of VA a key symptom of
alert? 0% 1% 22% 77%
(3) Do you consider the appearance of a central scotoma a key
symptom of alert? 0% 1% 21% 78%
(4) Do you consider a macular hemorrhage in a patient with
drusen a key symptom of alert? 0% 1% 5% 94%
(5) Do you consider the macular edema in a patient with drusen
a key symptom of alert? 0% 0% 21% 79%
(6) Do you consider the corrected VA an essential initial test? 0% 1% 8% 91%
(7) Do you consider the PPBMC an essential initial test? 0% 4% 9% 87%
(8) Do you consider the macular OCT an essential initial test? 0% 0% 6% 94%
(9) Do you consider the FA an essential initial test? 0% 18% 42% 40%
(10) Do you consider the loading doses (3 intravitreal injections)
the routine way to begin treatment in all cases? 2% 7% 21% 70%
(11) Do you consider the initial loading dose feasible from a
socio-sanitary point of view? 5% 15% 46% 34%
(12) Do you consider the PRN regimen (1 intravitreal injection +
PRN) the routine way to start treatment in all the cases? 35% 40% 18% 7%
(13) Do you consider a complete series of diagnostic tests
necessary during the loading phase? 25% 49% 12% 14%
(14) Do you consider a limited amount of diagnostic testing
necessary during the loading phase? 7% 39% 20% 34%
(15) Do you consider monthly complete examinations in the
PRN regimen feasible in NHS hospitals (Consider “complete
examination” VA, OCT PPBMC)?
35% 48% 15% 2%
(16) Do you consider monthly complete examinations in the
PRN regimen feasible in private hospitals (Consider “complete
examination” VA, OCT PPBMC)?
8% 27% 45% 20%
Individualized treatment therapy
(17) Do you have in consideration the balance of risk/profit in
deciding which guidelines to follow? 1% 6% 57% 36%
(18) Do you consider monthly treatment the most suitable
regimen? 16% 21% 40% 23%
(19) Do you consider monthly treatment feasible in NHS
hospitals? 73% 22% 3% 2%
(20) Do you consider monthly treatment feasible in public
hospitals? 30% 37% 28% 5%
(21) Do you consider the PRN regimen with monthly visits the
most suitable practice? 2% 25% 51% 22%
(22) Do you consider the PRN regimen with monthly visits
feasible in NHS hospitals? 32% 36% 30% 2%
(23) Do you consider the PRN regimen with monthly visits
feasible in private hospitals? 8% 24% 60% 8%
(24) Do you consider the T&E regimen the most suitable
practice? 3% 53% 38% 6%
(25) Do you consider the T&E regimen feasible in NHS
hospitals? 8% 38% 52% 2%
(26) Do you consider the T&E regimen feasible in private
hospitals? 5% 25% 58% 12%
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Table 1: Continued.
Question Almost never Sometimes Frequently Almostalways
(27) Do you consider the W&E regimen the most suitable
practice? 12% 56% 31% 1%
(28) Do you consider the W&E regimen feasible in NHS
hospitals? 2% 26% 67% 5%
(29) Do you consider the W&E regimen feasible in private
hospitals? 4% 19% 69% 8%
(30) Do you consider that, in general, most of the patients will
be properly treated with seven injections during the first year of
the treatment?
0% 10% 80% 10%
(31) Do you consider that, in general, most of the patients will
be properly treated with four injections during the second year
of the treatment?
1% 27% 52% 5%
(32) Do you consider it suitable to perform the intravitreal
injection on the same day of the follow-up visit? 3% 23% 22% 52%
(33) Do you consider it feasible to perform the intravitreal
injection on the same day of the follow-up visit in NHS
hospitals?
29% 43% 14% 14%
(34) Do you consider it feasible to perform the intravitreal
injection on the same day of the follow-up visit in private
hospitals?
5% 24% 42% 29%
(35) Aside from the logistical factors, if you have a clean room
in the consulting area, would you consider it appropriate to
perform an intravitreal injection there?
38% 19% 19% 24%
(36) Do you consider performing the intravitreal injection in a
clean room as safe as in the operating room? 13% 22% 32% 32%
(37) Do you consider it necessary that the retinal specialist
perform himself VA check? 25% 42% 20% 13%
(38) Do you consider it necessary that the retinal specialist
perform himself the OCT? 15% 32% 27% 26%
(39) Do you consider it necessary that the retinal specialist
perform himself the FA? 12% 20% 27% 41%
(40) Do you consider it necessary that the retinal specialist
perform by himself the PPBMC? 2% 16% 24% 58%
Nonresponders and referral to general ophthalmologist
(41) Do you consider an absolute nonresponder a patient with
worsening VA and OCT macular thickness post-treatment? 0% 1% 44% 55%
(42) In the case of a nonresponder, should the checkup interval
be reduced to 15 days since the last injection in order to test for a
response?
18% 48% 19% 15%
(43) In the case of a nonresponder, should the AGF and ICG be
repeated to rule out pathologies such as CP or RAP? 0% 13% 28% 59%
(44) Do you consider visual acuity less than 20/400 a criteria to
refer the patient to the GO? 13% 59% 22% 6%
(45) Do you consider visual acuity less than 20/200 a criteria to
refer the patient to the GO? 42% 49% 6% 3%
(46) Do you consider a fibrosis over 50% of the lesion
(disciform scar) criteria to refer the patient to the GO? 7% 48% 38% 7%
(47) Do you consider the absence of retreatment criteria during
the last 6 months a criterion to refer the patient to the GO? 37% 48% 15% 0%
(48) Do you consider the absence of retreatment criteria during
the last 9 months a criterion to refer the patient to the GO? 25% 34% 35% 6%
(49) Do you consider the absence of retreatment criteria during
the last 12 months a criterion to refer the patient to the GO? 13% 31% 33% 23%
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Table 1: Continued.
Question Almost never Sometimes Frequently Almostalways
















































VA: best corrected visual acuity; OCT: optimal coherence tomography; PPBMC: posterior pole biomicroscopy; FA: fluorescein angiography; NHS: National
Health System; PRN: pro re nata; T&E: treat and extend; W&E: wait and extend; ICG: indocyanine green angiography; CP: choroidal vascular polidopipathy;
RAP: retinal angiomatous proliferation; GO: general ophthalmologist.
with neovascular AMD, reducing both the burden of the
number of injections and follow-up visits [28]. However,
other studies with a less strict protocol found that when the
follow-up visits were gradually spaced out, themeanVA imp-
rovement was only 0.7 letters at 1 year [29].This indicates that
follow-up and treatment protocols in each hospitalmust be as
strict as possible, and audits must be periodically performed
to assure adherence. It is reasonable that strict protocols, as
these followed in clinical trials, may help to improve results
in real-life treatment of AMD patients.
The majority of retina specialists surveyed considered
that the best option is to perform intravitreal injections on the
same day of follow-up visit. However, they also believe that
to perform the injection on the same day represents a bigger
burden due to flow-chart organization reasons (Table 1).
Another issue is that many of the Spanish retinal physicians
prefer to inject in the operating room because it is safer [30]
(Table 1). In order to perform an injection on the same day as
the follow up visit, it is important to organize the clinic so as
to reduce the time spent per injection as well as minimizing
waiting times for appointments. Injecting on the same day
as the follow-up visit might avoid scheduling unnecessary
future appointments for the patient.
The treatment may be done in a clean room just as safely
as in an operating room as is recommended by the SERV
guidelines for intravitreal injections [31].Themost important
aspects are the previous topical administration of povidone
iodine, the use of sterile material and gloves, and an adequate
injection technique, rather than the treatment environment.
Finally, the injection may be performed by a trained oph-
thalmologist and it is not necessary that a retina specialist
perform the procedure.
Recently, the identification of “nonresponders” or “poor
responders” is relevant as these might require more visits and
injections. There is not any clear defined criterion to identify
such cases. In this Delphi study, the participant agreed that an
absolute bad responder is a patient losing visionwith anatom-
ical worsening after antiangiogenic therapy. In this case the
most frequent protocol identified in the survey is to perform
an indocyanine green angiography in order to identify as
the presence of polypoidal choroidal vasculopathy or retinal
angiomatous proliferation [32, 33].Themost frequently emp-
loyed second line treatment was combination therapy with
photodynamic therapy and antiangiogenic drugs [34]. The
second option was to swap the antiangiogenic drug [35]
(Table 1). It is possible that the former option will increase in
the future with the commercialization of new approved antia-
ngiogenic drugs like aflibercept [35].Most participants in this
study agreed that the best moment to determine the degree of
response of a patient to the initiated therapy is after finishing
the loading phase [36].
Another important gap is that once a patient has been
treated and followed in a hospital, hospital ophthalmologists
seldom refer this patient to the general ophthalmologist
although they have reached a low level of vision, or a disci-
form scar have developed (Table 1). This is probably because
some studies like HORIZON and SEVEN-UP have shown
that nv-AMDmay remain active for a number of years [9, 37].
However, sometimes treatment may be discontinued in pres-
ence of signs active disease [38, 39]. For example, treatment
may be deferred or terminated in situations where further
visual improvement appears unlikely, for example, severe
RPE tears involving the foveal center, or in the context of
significant coexisting geographic atrophy or subfoveal scar
formation [40]. In those cases the patient may be referred to
a general ophthalmologist in an outpatient setting.
In summary, after the most important deficiencies were
detected, an expert advisory panel used a new two-round
Delphi method to describe some recommendations in order
to reduce some of the problems detected.
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The results of antiangiogenic therapy could differ from the
results of clinical trials because these protocols are
frequently difficult to use in real clinical practice.
62,5 37,5 0 0 0
Ideally, a personalized retreatment that keeps in mind the
risks and benefits and avoids the over- and
undertreatment of the patient should be done.
75 25 0 0 0
Generally it is advisable to begin the treatment with a
loading phase of three injections. 87,5 12,5 0 0 0
In order to reduce assistance burden, complementary
examinations could be avoided during the loading phase
or be reduced to a minimum exploring only VA and OCT.
56,25 31,25 12,5 0 0
In some monitoring visits in which the treatment has been
previously decided, the examinations could be omitted. 43,75 37,5 12,5 0 6,25
It would be advisable that examinations such as VA and
OCT would be performed by technical staff, while the
ophthalmologist interprets the results and makes
treatment decisions
50 43,75 6,25 0 0
In case of following the PRN regimen, reinjection is
recommended in the case of evidence of disease activity in
the OCT, new hemorrhage or vision loss due to the disease
activity.
62,5 37,5 0 0 0
The T&E regimen could be a useful protocol to reduce the
number of revisions and the burden of the disease. 37,5 56,25 0 6,25 0
In the presence of a relapse it is recommended to continue
with the treatment until the retreatment criteria
disappears.
43,25 50 6,25 0 0
When retreating due to a relapse, if it is not possible to
follow established monitoring guidelines, a new loading
phase may be considered without performing the
associated examinations
37,5 56,25 6,25 0 0
Ideally, the relapses should be treated the same day they
are diagnosed. 62,25 25 12,5 0 0
It is as adequate and safe to perform intravitreal injections
in a clean room as in an operating room. 56,25 31,25 12,5 0 0
“Absolute” nonresponders are defined as those who after
the three loading doses still have worsening VA and OCT 68,75 31,25 0 0 0
In nonresponders, the guidelines have to be decided after
doing an ICG (to rule out diseases as CP or RAP) 62,5 31,25 6,25 0 0
It would be recommendable to refer patients to a general
ophthalmologist who have not presented with retreatment
criteria in the last 12 months or who have the disease in a
disciform state.
50 31,25 12,5 6,25 0
Ideally, a personalized retreatment that keeps inmind the
risks and benefits and avoid the over- and undertreatment
of the patient should be done. Generally it is advisable to
start the treatment with a loading phase of three injections. In
order to reduce assistance burden, complementary examina-
tions could be avoided during the loading phase or be reduced
to a minimum, exploring only VA and OCT if the patient
informs there is a problem. Moreover, in some monitoring
visits, in which the treatment has been previously decided,
the examinations could be omitted. It would be advisable that
examinations such as VA and OCT would be performed
by technical staff, while the ophthalmologist interprets the
results and makes treatment decisions. When following the
PRN protocol, reinjection is recommended in the case of
evidence of disease activity in the OCT, new hemorrhage or
vision loss due to the disease activity.The TER regimen could
be a useful protocol to reduce the number of follow-up visits
and the burden of the disease. In the presence of a relapse
it is recommended to continue with the treatment until the
retreatment criteria disappears. When retreating due to a
relapse, if it is not possible to follow established monitoring
guidelines, a new loading phase may be considered without
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performing the associated examinations. Ideally, the relapses
should be treated the same day they are diagnosed. It is as
adequate and safe to perform intravitreal injections in a clean
room as in an operating room. Absolute nonresponders are
defined as those who after the three loading doses still have
worseningVA andOCT. In nonresponders, the treatment has
to be decided after doing anindocyanine green angiography
(to rule out diseases such as polypoidal choroidopathy or
retina angiomatous proliferation). It would be recommend-
able to refer patients to a general ophthalmologist who have
not presented with retreatment criteria in the last 12 months
or who have the disease in a disciform state.
Although these are commonly occurring problems and
some suggested solutions, the authors acknowledge that not
all of these issues will apply to every clinic. Moreover, this
Delphi study was done with Spanish retina specialists and
the problems may not be the same in NHS from different
countries. However, it is vital to detect the main bottlenecks
in hospitals and clinical services to provide a fast and efficient
service for patients with nv-AMD.
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